Development and in vitro evaluation of buccoadhesive carvedilol tablets
- PMID: 17507315
- DOI: 10.2478/v10007-007-0015-7
Development and in vitro evaluation of buccoadhesive carvedilol tablets
Abstract
Buccoadhesive tablets of carvedilol were prepared using HPMC K4M, HPMC K15M and Carbopol 934 as mucoadhesive polymers. Fifteen formulations were developed with varying concentrations of polymers. Formulations of the BC or BD series were composed of HPMC K4M or HPMC K15M in ratios of 1:1 to 1:5 whereas in the BE series Carbopol 934 was used (1:0.25 to 1:1.50). The formulations were tested for in vitro drug release, in vitro bioadhesion, moisture absorption and in vitro drug permeation through porcine buccal mucosa. Formulation BC3 showed maximum release of the drug (88.7 +/- 0.4%) with the Higuchi model release profile and permeated 21.5 +/- 2.9% of the drug (flux 8.35 +/- 0.291 microg h(-1)cm(-2)) permeation coefficient 1.34 +/- 0.05 cm h(-1)) through porcine buccal membrane. BC3 formulation showed 1.62 +/- 0.15 N of peak detachment force and 0.24 +/- 0.11 mJ of work of adhesion. FTIR results showed no evidence of interaction between the drug and polymers. XRD study revealed that the drug is in crystalline form in the polymer matrix. The results indicate that suitable bioadhesive buccal tablets with desired permeability could be prepared.
Similar articles
-
Development of mucoadhesive patches for buccal administration of carvedilol.Curr Drug Deliv. 2007 Jan;4(1):27-39. doi: 10.2174/156720107779314785. Curr Drug Deliv. 2007. PMID: 17269915 Clinical Trial.
-
Design and in vivo evaluation of carvedilol buccal mucoadhesive patches.Pak J Pharm Sci. 2008 Jul;21(3):241-8. Pak J Pharm Sci. 2008. PMID: 18614419 Clinical Trial.
-
Development of novel bioadhesive buccal formulation of diltiazem: in vitro and in vivo characterization.PDA J Pharm Sci Technol. 2009 Sep-Oct;63(5):401-8. PDA J Pharm Sci Technol. 2009. PMID: 20158046 Clinical Trial.
-
Design of a novel controlled-release formulation of carvedilol: pharmacology and clinical aspects. Introduction.Am J Cardiol. 2006 Oct 2;98(7A):1L-4L. doi: 10.1016/j.amjcard.2006.07.013. Epub 2006 Aug 28. Am J Cardiol. 2006. PMID: 17023226 Review. No abstract available.
-
Recent developments of nanoparticle-delivered dosage forms for buccal delivery.Int J Pharm. 2019 Nov 25;571:118697. doi: 10.1016/j.ijpharm.2019.118697. Epub 2019 Sep 14. Int J Pharm. 2019. PMID: 31526839 Review.
Cited by
-
Preparation and characterisation of fluconazole vaginal films for the treatment of vaginal candidiasis.Indian J Pharm Sci. 2013 Sep;75(5):585-90. Indian J Pharm Sci. 2013. PMID: 24403660 Free PMC article.
-
A clinical perspective on mucoadhesive buccal drug delivery systems.J Biomed Res. 2014 Mar;28(2):81-97. doi: 10.7555/JBR.27.20120136. Epub 2013 Jun 6. J Biomed Res. 2014. PMID: 24683406 Free PMC article. Review.
-
Development of Bioadhesive Buccal Tablets of Nicorandil Using a Factorial Approach.Turk J Pharm Sci. 2020 Aug;17(4):388-397. doi: 10.4274/tjps.galenos.2019.09226. Epub 2020 Aug 28. Turk J Pharm Sci. 2020. PMID: 32939134 Free PMC article.
-
A review on bioadhesive buccal drug delivery systems: current status of formulation and evaluation methods.Daru. 2011;19(6):385-403. Daru. 2011. PMID: 23008684 Free PMC article.
-
Formulation and optimization of mucoadhesive buccal patches of losartan potassium by using response surface methodology.Adv Biomed Res. 2015 Oct 29;4:239. doi: 10.4103/2277-9175.168606. eCollection 2015. Adv Biomed Res. 2015. PMID: 26682205 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources